Keywords
How to Cite
Abstract
Laboratory monitoring of replacement therapy in hemophilia B consists of measuring factor IX activity before and after infusion. Discrepancies were observed in the monitoring of modified products (EHL) when they are measured by different methods: one-stage assay (OSA) or chromogenic assay (CSA) and still within the same method. It is recommended that each hemophilia center have its assay validated for the product used in the infusion. Assays calibrated with a traceable calibrator against a WHO standard should be used. In the monitoring of FIX, extreme care must be taken when choosing the assay due to the great variability of results found between the different EHL products
References
2. Fundamentos para el manejo práctico en el laboratorio de Hemostasia Grupo CAHT 2da Edición.
3. WFH Guidelines for the Management of Hemophilia, 3rd edition, Chapter 3: Laboratory Diagnosis and Monitoring. Haemophilia, Vol 26, Issue S6, Agosto 2020.
4. Rosen P, Rosen S, Ezban M, Persson E. Overestimation of N-glycoPEGylated factor IX activity in a onestage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016; 14: 1420-7.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar